175 related articles for article (PubMed ID: 37283769)
41. A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.
Chen W; Lin W; Wu L; Xu A; Liu C; Huang P
Int J Med Sci; 2022; 19(2):377-392. PubMed ID: 35165523
[No Abstract] [Full Text] [Related]
42. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
43. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
44. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
Liu Z; Miao J
Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
[TBL] [Abstract][Full Text] [Related]
45. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
[TBL] [Abstract][Full Text] [Related]
46. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
47. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
48. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
49. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
50. CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers.
Zhang H; Yang Z; Du G; Cao L; Tan B
Technol Cancer Res Treat; 2021; 20():1533033820980088. PubMed ID: 33576304
[TBL] [Abstract][Full Text] [Related]
51.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
52. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
53. A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Qin YY; Yang Y; Ren YH; Gao F; Wang MJ; Li G; Liu YX; Fan L
Medicine (Baltimore); 2023 Nov; 102(45):e35829. PubMed ID: 37960824
[TBL] [Abstract][Full Text] [Related]
54. Effects of SVEP1 on Lung Squamous Cell Carcinoma and its Association with Tumor Mutation Burden, Prognosis, and Immune Regulation.
Luo Y; Zhang M; Wang Z; Li Z; Chen X; Cao J; Que J; Chen L; Deng X
Comb Chem High Throughput Screen; 2023; 26(2):313-329. PubMed ID: 35306983
[TBL] [Abstract][Full Text] [Related]
55. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
56. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
Zhang S; Xiong H; Yang J; Yuan X
Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
[TBL] [Abstract][Full Text] [Related]
57. The Pan-Cancer Crosstalk Between the
Xie R; Yuan M; Jiang Y
Front Cell Dev Biol; 2022; 10():790947. PubMed ID: 35309935
[No Abstract] [Full Text] [Related]
58. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
59. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
60. HOXC11 functions as a novel oncogene in human colon adenocarcinoma and kidney renal clear cell carcinoma.
Cui Y; Zhang C; Wang Y; Ma S; Cao W; Guan F
Life Sci; 2020 Feb; 243():117230. PubMed ID: 31923422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]